Follow us: 
Downloads
NEW: download our 5 pages Management summary
BMSystems business & POC cases studies Presentation
BMSystems' Scientific Presentation
Targeted cancer therapies future failures and novel strategy
The presentation why did we need to change the discovery paradigm?
The management summary why did we need to change the industry paradigm
What are the differences & synergies between Heuristic and Mathematical approaches?
Synthons Industrial biotech program
Additional Info
Cochin Institute: training presentation
CMC Strategy Europe Forum Adebiotech/BMSystems Presentation
BMSystems know-how and Technologies
BMSystems know-how (non-confidential)
CADI™ Global discovery & validation process exploiting Smart Data
(contextualized, with patients based lines, related to mechanisms data)
BMSystems Technologies (non-confidential)
- Computer-Assisted Deductive Integration (CADI™) proprietary methodologies and tools.
- CADI™ Search (data acquisition & mining).
- CADI™ Architect (data organization & structuring).
- CADI™ Fiber-N (integrative engine).
- CADI™ View (model representation & visualization).
- TAPE Patent: WO/2008/093010- December 2006. A technology allowing to rapidly & simultaneously introduce defined densities of random mutations in any number of selected regions within a gene while conserving intact any number of defined coding domains in this same gene (applicable to all proteins, including antibodies, enzymes, etc..).
- AB-ACCUS patent: WO/2008/093009 - December 2006. A recombination technology allowing the rapid & efficient production of phage banks in which every individual differs from all others for any number of selected genes or other sequences.
- RIPh patent: PCT/FR2010/050796 – May 2009. A methodology allowing to reversibly immobilize an obligate lytic phage within its bacterial host and to then extensively modify its genome without adversely affecting the phage's replicative ability.
- CNS copatent: WO/2010/029131 - September, 2008 (psychiatric & neurological disorders). Dose reduction: use of anti-connexin agents for modulating the therapeutic effect of psychotropic & neurological drugs and preclinical evaluation platform patent, filed with CEA Life Sciences.